Aqemia, a Paris, France-based techbio firm that teaches atomic scale physics to a generative AI to develop new medicines, raised $38M in funding.
The spherical, which introduced the overall quantity to $100M, was led by Cathay Innovation, adopted by historic buyers Wendel, Bpifrance Giant Enterprise, Eurazeo, and Elaia.
The corporate intends to make use of the funds to assist its growth objectives, together with preparations for medical trials.
Led by CEO Maximilien Levesque, Aqemia is a techbio firm constructing drug discovery pipelines for crucial ailments. It has already achieved a number of drug discovery successes inside its inner pipeline and thru collaborations with pharmaceutical corporations, with its packages presently present process in vivo optimization.
Along with reaching the $100M funding milestone, the corporate introduced the opening of its London workplace, scheduled for January 2025 within the King’s Cross space. This growth strengthens its presence within the UK’s dynamic tech and biotech sectors. The brand new location will present entry to the UK’s wealthy expertise pool, particularly in life sciences and techbio, as the corporate continues its world recruitment efforts throughout all ranges.
FinSMEs
10/12/2024
